tbuckley/cabot-search huggingface dataset:
Knowledge-attitude-practice of chronic kidney disease among type 2 diabetic patients in a township of Shanghai suburb
Authors: Shuai Liu, Hengqing Cui, Xia Chen, Haidong He, Weiying Gu, Zheng Qi
Journal: BMJ (2018)

A total of 510 patients with type 2 diabetics mellitus (T2DM) from Huacao Township of Shanghai suburb were enrolled in the study. The gender, age, duration for diabetes, HbA1c level, blood pressure level, obesity status and health education of chronic kidney disease (CKD) were recorded. The knowledge, attitude and practice (AKP) of the subjects regarding prevention and treatment of CKD were assessed by using a self-restraint questionnaire. The data were analyzed with logistic regression. The knowledge awareness rate, attitude positive rate and behavior execution rate were 44.1% (225/510), 49.0% (250/510) and 16.5% (84/510), respectively. Scores of knowledge, attitude, behavior and medication compliance of the subjects were 16.8±4.8, 18.3±3.6 and 13.1±4.1, respectively. The attitudes were closely related to educational level, HbA1c level, systolic blood pressure, obesity, health education history, and awareness level of CKD; behaviors were closely related to education level, systolic blood pressure, obesity, health education history and CKD prevention and treatment(P<0.05).


Key words: 
Diabetes mellitus, type2; Kidney disease, chronic; Health knowledge, attitude, Practice; Sickness impact profile
Analysis of 41 cases with functional dyspepsia complicated by psychological disorders
Authors: Qi-bin Jia, Li Li, Ying Yin, Yu-jing Fan, Yu Lan
Journal: BMJ (2011)

In our gastroenterology clinic from Jun. 2008 to Jan. 2009, 20. 9% (277/1320) patients were diagnosed with functional dyspepsia (FD) and 14. 8% (41/277) of them with psychological problems according to Minnesota Multiphasic Personality Inventory (MMPI). In those with psychological disorders,92.7% were found with somatization, 60. 9% with depression and anxiety, 97.6% with abdominal pain,75.6% with bloating, 63.4% with early fullness and 36. 6% with nausea. More than 80% patients with anxiety and depression complained irritability, worry, fatigue, poor concentration, memory loss and insomni.a. After 4 weeks of psychological consultation and anti-depression treatment, 5 patients had significant improvement, 31 had improvement and 3 had no response. The overall response rate was 87. 8%.In summary,there is a high prevalence of depression and anxiety in population with FD. Hypochondria and somatization are common among these patients. Psychological consultation with anxiolytic drugs may have good therapeutic effects.

Key words: 
Dyspepsia;  Anxiety;  Depression
Value of MRI in diagnosis of oblique vaginal septum syndrome
Authors: Jielin Xie, Guofu Zhang, Zhigang Han, Xiaomei Tian
Journal: BMJ (2017)

Objective
To assess the application of MRI in diagnosis of oblique vaginal septum syndrome (OVSS).


Methods
Clinical and imaging data of 41 patients with OVSS confirmed by surgery from March 2011 to November 2016 were retrospectively analyzed.


Results
The average age of patients was 20.5 year (10-46 years). The primary clinical symptoms were menorrhalgia (16 cases) and menorrhagia (13 cases). There were 12 cases of type Ⅰ, 23 cases of type Ⅱ, 5 cases of type Ⅲ and 1 case of type Ⅳ among 41 cases of OVSS.The resections for OVSS were performed in 35 cases.Forty two cases were diagnosed as OVSS by MRI scan, and 41 were confirmed by surgery, the accuracy of MRI diagnosis was 97.6%(41/42). MRI showed uterus didelphys, hydrocolpos or hematocolpos with varying degrees, and revealed ipsilateral renal agenesis in all 41 cases.


Conclusion
MRI scan can accurately diagnose oblique vaginal septum syndrome and provide comprehensive information for clinical treatment.


Key words: 
Oblique vaginal septum syndrome; Vaginal diseases; Magnetic resonance imaging; Urogenital abnormalities
Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).
Authors: J. Randolph Hecht, Miklos Pless, Antonio Cubillo, Aitana Calvo, Hong Jae Chon, Chunxu Liu, Wendy Snyder, Emily Chan, Marya F. Chaney, Jason Alan Chesney, Aleix Prat
Journal: Journal of Clinical Oncology (2020)

3015 Background: T-VEC is a genetically modified, oncolytic HSV-1 designed to selectively replicate within tumors and produce GM-CSF to enhance systemic antitumor immunity. The safety and efficacy of T-VEC in treatment of advanced melanoma has been demonstrated as monotherapy and in combination with checkpoint inhibitors (Andtbacka JCO 2015, Chesney JCO 2017, Ribas Cell 2017). T-VEC has also demonstrated tolerable safety for intrahepatic inj (Hecht JCO 2018). This phase 1b, multicenter, open-label, dose escalation study (NCT02509507) evaluates the safety of intrahepatic inj of T-VEC in combination with intravenous (IV) pem in patients (pts) with hepatocellular carcinoma (HCC) or liver metastases (mets). Methods: The primary objective is to assess the maximum tolerated concentration (MTC) of T-VEC inj into liver tumors based on the incidence of dose-limiting toxicities (DLTs). DLT rate was evaluated with the mTPI up-and-down design. Eligible pts were ≥ 18 years, had progressive HCC or breast cancer, colorectal cancer, gastroesophageal cancer, melanoma, non-small cell lung cancer, or renal cell cancer liver mets, with measurable liver tumors suitable for inj. This dose escalation study comprised 2 groups: A (non-HCC) and B (HCC). T-VEC was given initially at 10 6 plaque-forming units (PFU)/mL followed by up to 4 mL of 10 7 PFU/mL (cohort 5) or 10 8 PFU/mL (cohort 6) every 21 (±3) days (Q21D). Inj volume was based on lesion size. Pem (200 mg) was given IV Q21D. Results: Here we report on three cohorts: A5 (10 7 PFU/mL T-VEC + pem), A6 (10 8 PFU/mL T-VEC + pem), and B5 (10 7 PFU/mL T-VEC + pem). Twenty-nine pts were treated: 7 in A5, 17 in A6, 5 in B5. Median age was 61 years (range: 30, 76). Median number of inj was 4 and median treatment duration was 88 days. One DLT of cholestatic hepatitis was observed out of 6 DLT evaluable pts in cohort A5. No DLTs were observed in cohort A6 and B5. MTC was 10 8 PFU/mL in non-HCC patients; exploration of MTC in the HCC population is ongoing. Treatment-emergent adverse events (TEAEs) were consistent across cohorts. The most common treatment-emergent treatment-related adverse events (TETRAE) were pyrexia (79.3%), chills (37.9%), and nausea (37.9%). Eight pts (27.6%) had grade 3/4 TEAEs: 2pts (6.9%) related to the combination therapy and the rest not related to treatment. No fatal AEs were observed. Conclusions: T-VEC intrahepatic inj in combination with IV pem at standard doses has thus far been demonstrated as feasible and tolerable to continue further investigation. Clinical trial information: NCT02509507 .
Efficacy and safety of apatinib combined with TACE in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Authors: Wei Zhang, Zhiping Yan
Journal: Journal of Clinical Oncology (2020)

e15504 Background: Effective options for patients with advanced hepatocellular carcinoma (HCC) are urgently needed. Studies have shown that combination of sorafenib with TACE could imorove survival for the treatment of locoregional HCCs. Apatinib is a novel and highly selective inhibitor of VEGFR2 tyrosine kinase. We were aiming to explore the efficacy and safety of apatinib combined with TACE in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Methods: This was a single-center single-arm phase 2 study. The key inclusion criteria included: (1) Histologicaly and cytologicaly diagnosed as Hepatocellular carcinoma of the liver ( HCC ) and with at least one imaging examination of measurable lesions, CT or MR scan long diameter of tumor ≥ 10 mm. (2) BCLC B / C; (3) Progressed after at least twice TACE. Eligible pts received apatinib at 500 mg/day for a maximum after TACE 4-7 days, and TACE treatment was performed after 4 days of discontinuation of apatinib until unacceptable toxicity or tumor recurrence. The primary endpoint was time to progression (TTP), which was defined as the time from enrollment to disease progression. The secondary endpoint was overall survival (OS) and treatment safety. Results: From May 27, 2018 to Oct 12, 2019, 22 pts wereenrolled. 5 pts received TACE more than 5 times, and 17 pts received TACE within 4 times. For 20 evaluable pts, two pts achieved partial response (10%), and 13 patients achieved stable disease. The ORR and DCR were 10% and 75%, respectively. At the cutoff data of Nov 4, 2019, 5 pts were still on treatment. 16 recurrenced and 5 death occurred. The mTTP was 5.09 months (95% CI, 3.48-7.16), and the mOS was not reached. Treatment-related adverse events occurred in 12 pts (60%). Seven grade 3 or 4 adverse events were reported (35%), respectively wereascites (2), platelet count decrease (1), elevated ALT/AST (1), hypertension (1), proteinuria (1) and nausea (1). None of the treatment related AEs was fatal. Conclusions: Apatinib combined with TACE might be effective and tolerant in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Clinical trial information: NCT03510416.
BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C–deficient mice
Authors: Gaelle Auguste, Leila Rouhi, Scot J. Matkovich, Cristian Coarfa, Matthew J. Robertson, Grazyna Czernuszewicz, Priyatansh Gurha, Ali J. Marian
Journal: Journal of Clinical Investigation (2020)

Mutation in the LMNA gene, encoding lamin A/C, causes a diverse group of diseases called laminopathies. Cardiac involvement is the major cause of death and manifests as dilated cardiomyopathy, heart failure, arrhythmias, and sudden death. There is no specific therapy for LMNA-associated cardiomyopathy. We report that deletion of Lmna in cardiomyocytes in mice leads to severe cardiac dysfunction, conduction defect, ventricular arrhythmias, fibrosis, apoptosis, and premature death within 4 weeks. The phenotype is similar to LMNA-associated cardiomyopathy in humans. RNA sequencing, performed before the onset of cardiac dysfunction, led to identification of 2338 differentially expressed genes (DEGs) in Lmna-deleted cardiomyocytes. DEGs predicted activation of bromodomain-containing protein 4 (BRD4), a regulator of chromatin-associated proteins and transcription factors, which was confirmed by complementary approaches, including chromatin immunoprecipitation sequencing. Daily injection of JQ1, a specific BET bromodomain inhibitor, partially reversed the DEGs, including those encoding secretome; improved cardiac function; abrogated cardiac arrhythmias, fibrosis, and apoptosis; and prolonged the median survival time 2-fold in the myocyte-specific Lmna-deleted mice. The findings highlight the important role of LMNA in cardiomyocytes and identify BET bromodomain inhibition as a potential therapeutic target in LMNA-associated cardiomyopathy, for which there is no specific effective therapy.
长效胰岛素类似物的临床应用
Authors: 傅汉菁
Journal: BMJ (2012)

长效胰岛素类似物作为一种基础胰岛素比临床常用的中效胰岛素具有作用时间长、每天注射一次、平稳无峰、低血糖发生少、变异率低的优点,可更好地模拟生理性基础胰岛素分泌,是目前临床应用基础胰岛素的最佳选择。
Clinical analysis of urethral cancer recurrence after radical cystectomy: a report of 18 cases
Authors: Hengbing Wang, Guangbo Fu, Liucheng Wang, Hao Liang, Xiaobing Niu, Zongyuan Xu, Peijin Hou, Xiaosong Yang, Yunyan Wang, Gongcheng Wang, Shuo Gu, Kun Liu
Journal: BMJ (2014)

Retrospective analyses were conducted for the incidence and diagnosis and treatment of 18 patients with urethral cancer recurrence among 206 patients after radical cystectomy between the year 2003-2007 and 2008-2013. The recurrence rates of urethral cancer were 8.7%, 14.3% from 2003 to 2007 and 5.4% from 2008 to 2013. The recurrence of urethral cancer was correlated with primary bladder tumor size, multiple tumor, tumor site and pathologic grading. With the strict enforcement of bladder cancer guideline, urethral cancer incidence tends to decrease. Prophylactic urethral resection should be applied if positive margins are found during cystectomy for bladder cancer, or when tumor has involved prostate, bladder neck and trigone or multiple tumors recur. Urethrectomy is an effective treatment of urethral cancer.


Key words: 
Cystectomy; Urethral neopalsms
Response to: ‘Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’’ by Nikpour<i>et al</i>
Authors: Alexis Mathian, Zahir Amoura
Journal: Annals of the Rheumatic Diseases (2020)

We thank Nikpour et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19 in a case series of 17 patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ).1 2 As mentioned in our study, we did not intend to analyse the incidence rate and the severity of COVID-19 in SLE because we are aware that our cohort most likely over-represents the most symptomatic and severe cases, resulting from a selection bias. Our conclusion was rather that patients with SLE treated with HCQ are not universally protected from COVID-19, a finding recently confirmed in another observational study in which data collected through the COVID-19 Global Rheumatology Alliance registry were analysed.3 

We agree with Nikpour et al that it is next to impossible to identify the …
Characterization of BDG8: An antibody-human IL-2 complex that selectively activates the effector arm of the immune system.
Authors: Timothy Wyant, Inbar Amit, Itay Levin, Natali Levitan, Noam Grossman, Olga Bluvshtein, Ruet Barak, Guy Nimrod, Sharon Fischman, Marek Strajbl, Yehezkel Sasson, Michael Zehnin, Yanay Ofran
Journal: Journal of Clinical Oncology (2020)

e15004 Background: Interleukin 2 is a 15.4 kDa type I cytokine of the four helix bundle structure. IL-2 signaling has two opposite effects, it can enhance immune response by activation of effector cells and regulate immune response by activation proliferation of regulatory T cells (Tregs). IL-2 mediates its effect by binding to two forms of IL-2 receptor: i) trimeric receptors made of IL-2Rα (CD25), IL-2Rβ (CD122), and a common IL-2Rγ (γc, CD132) chains or ii) a dimeric receptor of only the IL-2Rβ and IL-2Rγ subunits. In Tregs, activation of the trimeric receptor is associated with FoxP3 mediated transcription leading to the production of suppression factors. Tregs express higher levels of the αβγ trimeric IL-2 receptor than effector cells. However binding of IL-2 to the βγ dimer is associated with activation of effector cells expressing relatively high levels of the βγ dimer and express low levels of trimer. High dose IL-2 therapy is used in melanoma and metastatic renal cell carcinoma with response rates 10%-15%. While efficacious, this approach has several disadvantages: 1) IL-2 dependent adverse effects such as Vascular Leak Syndrome (VLS) excluding many patients from being considered 2) The short half-life of IL-2 requires frequent administration, resulting in repeated spikes in the level of circulating IL-2. 3) Administered IL-2 is not selective and enhances a non-desired activation of Tregs. Methods: Antibodies were computational designed to bind to a specific epitope on Il-2 allowing for the binding to the CD122/CD132 complex and exclude the CD122/CD132/CD25 complex. Results: Here we show that we specifically designed and tested a humanized antibody (BD8) that: i) binds tightly the human IL-2 (hIL-2) and ii) the antibody- hIL-2 complex preferentially to bind the IL-2Rβ sub-unit and blocks the IL-2Rα subunit. We show administering the BD8 Ab-IL-2 complex to C57BL/6 mice has a profound effect on activation of MP CD8+, NK and NKT effector cells with minimal effect on Tregs. In mice the antibody-hIL-2 complex serum half -life is much longer then the half-life of hIL-2. In the B16-F10 Melanoma model, BD8-hIL2 resulted in robust effect compared to hIL-2 alone. Conclusions: BD8 is a computationally designed antibody specifically binds to IL-2 inducing the activation of effector cells without stimulating Tregs and demonstrates efficacy in animal cancer models.
老年急性冠状动脉综合征136例感染因素分析
Authors: 关小红
Journal: BMJ (2005)

急性冠状动脉综合征( ACS)是老年人常见的急症,现将136例老年ACS的感染因素总结如下. 1.临床资料:136例为我院老年病科1998年1月至2003年6月的住院患者,男101例,女35例,年龄60～89岁(平均70.5±2.1)岁.诊断为不稳定型心绞痛(UA)、急性心肌梗死(AMI),诊断符合相关标准[1,2].其中UA 112例(82.4%),AMI 24例(17.6%).136例中排除心外病变所致心电图、心肌酶改变,排除非冠心病心脏疾患。
慢性光化性皮炎一例
Authors: 俞新民, 吴莉菲, 吴绍芳
Journal: BMJ (2008)

患者男,68岁,农民.因面部、双手等暴露部位红斑肿胀伴瘙痒5年就诊.5年前患者出现颜面、颈后、手背红斑肿胀伴瘙痒,抓后渗出,曾在某医院诊断为湿疹,治疗有好转但未痊愈.其后疾病反复发生,范围逐渐扩大,皮肤变黑增厚,有色素脱失,波及后背及股外侧,夏重冬轻.近5 d来,由于病情加重,来我院就诊,发病以来无全身症状.既往体健,否认家族类似疾病史。
组织多普勒超声心动图方法学的标准化和规范化的实践体会与初步建议
Authors: 朱天刚
Journal: BMJ (2006)

近年来,由于计算机技术的突飞猛进,超声心动图的图像质量得到极大的提高,组织多普勒及其相关技术不断发展和更新,组织多普勒超声心动图在心脏同步化治疗中的作用越来越受到临床的重视.但目前,不论国外还是国内,组织多普勒超声心动图尚无明确的方法学和临床应用指南,导致组织多普勒超声心动图的测量结果出现较大的误差.为了避免和减少由于方法学所造成的误差,我们有必要对其方法学进行标准化和规范化,只有这样才能使我们在方法学上保持一致,结果具有可比性。
认识并重视感冒
Authors: 何权瀛
Journal: BMJ (2011)

英国小说家、剧作家Herbert曾经说过:我喜欢医生,因为你们是神圣的,但是为什么你们宁可年复一年地去研究哪些罕见、离奇的疾病,却让我们这些人,无论男女老少,常常被小小的感冒而困扰呢?或许感冒还是没能引起你们的足够重视.这段话充分表达出感冒看似小,但对人们生活的影响并不小。
Application of standardized patients in training of communication skills in consultation for resident general practitioners
Authors: Sun-fang Jiang, Yuan Zhang, Rong Zhou, Shan-zhu Zhu
Journal: BMJ (2010)

Objective To assess roles of standardized patients (SPs) in training of communication skills for resident general practitioners (GP). Methods Fifty-two resident GPs were trained for communication skills in consultation with SPs during May to July, 2008, including information feedback from SPs, lectures and group discussion coordinated by instructors on problems developed during residents' clinical encounters. Communication skills of the trainees with patients was assessed before and after training, respectively, including building physician-patient relationship, collecting information and providing feedback, understanding complaints from patients' perspective, sharing information and obtaining informed consents and closing consultation. Assessment was scored and proportion of trainees qualified for consultation with SPs were estimated. Results Total score of the trainees was higher after training than that before it (76 ± 13 vs. 49 ± 12, P ＜ 0. 01 ), and 86. 5 percent of them qualified for their communication skills after training, as compared to that of 15.4 percent before it. Proportions of the trainees qualified for building physician-patient relationship, collecting information and providing feedback, understanding complaints from patients' perspective, sharing information and obtaining informed consents during consultation were higher after training than those before it (90. 4% vs. 59. 6%, 65.4% vs. 5.8%, 38.5% vs. 11.5%, 86. 5% vs.17.3% and 65. 4% vs. 3. 9%, respectively, all P ＜0. 01 ). Scores of physician-patient communication in the trainees correlated with those of their consultation skills both before and after training ( r = 0. 55 and r =0. 63, both P ＜ 0. 01 ). Increase in scores of physician-patient communication and consultation skills in trainees after training also associated with that in those of clinical skills ( r = 0. 62, P ＜ 0. 01 ). Conclusions Application of SPs can effectively enhance communication skill of resident general practitioners, thus improve their competencies in clinical consultation.

Key words: 
Teaching;  Patient simulation;  Clinical competency
慢性乙型肝炎患者心理状况和生存质量的调查
Authors: 王新敏, 李春波, 沈昭在, 余金明
Journal: BMJ (2009)

慢性乙型肝炎病毒感染在全世界一直都是一个严重的健康卫生问题.中国乙型肝炎患者众多,目前治疗上主要重视躯体疾病的治疗而较少关心此类患者的心理状况,本研究调查慢件乙型肝炎患者的心理状况和生存质量现状,以期能引起大家的重视。
Comparative survival analysis of melanoma patients with secondary papillary thyroid carcinoma using Surveillance, Epidemiology, and End Results (SEER) data
Authors: E. D. Whitman, R. T. Bustami
Journal: Journal of Clinical Oncology (2009)

9068 Background: Malignant melanoma (MM) and papillary thyroid cancer (PTC) may share genetic mutations. The expected mortality of a patient with both MM and PTC should be predominantly influenced by MM and unchanged by the PTC diagnosis, unless shared genetic abnormalities or other factors alter the phenotype of either or both diseases. We hypothesize patients with both MM and PTC have altered mortality risk compared to patients with either cancer alone. Methods: The study population included patients identified in the SEER 1973–2004 database who were diagnosed with MM or PTC as a primary tumor. The population was divided into four groups: (1) patients with MM only (MEL); (2) patients with PTC only (PAP); (3) patients who developed MM as a second primary after PTC (2MEL); and (4) patients diagnosed with PTC after MM (2PAP). Time between diagnosis and death or last follow up (December 2005) and other demographic data was obtained from SEER. Comparisons between the group death rates were made using the Chi-Square Test. A Cox proportional hazards regression model, adjusted for patient characteristics, predicted the risk of death and survival by group. Results: 9575 SEER patient records were included: 6622 in MEL, 2778 in PAP, 113 in 2MEL and 62 in 2PAP. Overall, 2095 patients (22%) died. There was a significant difference in mortality rates between the groups: MEL 27%, PAP 9%, 2MEL 21% and 2PAP 18%, p&lt;0.001 by Chi-Square. Controlling for other variables in a multivariate Cox model, patients in the 2MEL group were significantly less likely to die than MEL patients (HR 0.52, 95% CI 0.35–0.79, p=0.002). 2PAP patients, the smallest sample, also had a reduced likelihood of death that did not reach statistical significance (HR=0.75, 95% CI 0.42–1.37, p=.35). PAP patients had the best survival (HR=0.43, 95% CI 0.36–0.50,p&lt;0.001). Other factors (age, race, gender and radiation therapy, data not shown) also significantly affected mortality. Conclusions: This study suggests that MM patients also diagnosed with PTC are more likely to survive than patients with MM alone. Identification of the causative factor(s) for this survival benefit will require additional epidemiologic and genetic studies. No significant financial relationships to disclose.
肝衰竭合并口腔真菌感染194例分析
Authors: 许海苗, 苏海滨, 王慧芬, 赵鸿, 林芳, 牟劲松, 闫涛, 李雷, 李晨
Journal: BMJ (2007)

回顾性分析194例肝衰竭患者合并口腔真菌感染的情况.发生在急性及亚急性肝衰竭患者8例,慢加急性肝衰竭88例,慢性肝衰竭98例,186例(95.9%)存在腹水、腹膜炎、水电解质紊乱甚至肝性脑病、败血症等多种并发症.病原菌以白色念珠菌为主(85.1%),其次为曲霉菌和其他念珠菌属.168例患者有抗生素应用史(86.6%),应用激素及免疫抑制剂者81例(41.8%).最佳防治措施是合理使用抗生素和激素,同时应警惕深部真菌感染的发生,一旦发生,愈后较差。
缺血性肝炎36例的临床表现
Authors: 李振方, 赵琦, 李红, 徐昌青
Journal: BMJ (2006)

观察36例缺血性肝炎患者的临床特征、生化指标和组织学特点.结果显示,缺血性肝炎主要为原发病、低血容量或休克的临床表现,谷氨酸氨基转移酶、天冬氨酸氨基转移酶、乳酸脱氢酶变化明显,总胆红素、直接胆红素等有不同程度的升高,肌酸激酶无明显变化,组织学变化轻微,与酶学变化不一致。
横膈下结肠嵌入综合征三例分析
Authors: 杨春普
Journal: BMJ (2008)

例1 女性,58岁.因咳嗽、左上腹胀痛、排气不排便6 d,于2007年10月29日就诊.既往史:高血压、脑血栓后4年,尚能站立行走.查体:血压:170/64 mm Hg(1 mm Hg=0.133 kPa),双肺偶闻干鸣音,心律不齐,闻及早搏.上腹略膨,全腹软,上腹及左上腹轻压痛,叩呈鼓音,肠鸣音活跃,未闻气过水声。
An artificial intelligence decision support system for the management of type 1 diabetes
Authors: Nichole S. Tyler, Clara M. Mosquera-Lopez, Leah M. Wilson, Robert H. Dodier, Deborah L. Branigan, Virginia B. Gabo, Florian H. Guillot, Wade W. Hilts, Joseph El Youssef, Jessica R. Castle, Peter G. Jacobs
Journal: Nature Metabolism (2020)